



All about skin and hair bioscience!

State-of-the-art technology and expertise for all your pre-clinical, mechanistic, and clinical needs in dermatology research.

- Pre-clinical Research
- Clinical Research
- Education







"We combine
our unique expertise,
our project design creativity,
and our passion to advance
our clients' success in
delivering novel and gamechanging skin and hair
research solutions"

President: Prof. Dr. Ralf Paus

## Monasterium Laboratory

Skin & Hair Research Solutions GmbH

Mendelstr. 17, 48149 Münster, Germany Phone: +49 (0) 251 93264-458 Fax: +49 (0) 251 93264-457

www.monasteriumlab.com

## For inquiries, please contact:

CFO:

Dr. Marta Bertolini (PhD)

m.bertolini@monasteriumlab.com

+ 49 (0)251 93263-080

Download flyer




# TriNetX: Real-world data for life sciences and healthcare industries

#### The database

- Over 120 million electronic health records (EHRs)
- 5 Unique Networks
  - Demographics
  - Diagnoses
  - Medications
  - Procedures
  - Laboratory and vitals
  - Genetics (limited)


#### Access though our experienced partners

- EBioMedicine. 2023 Jul;93:104639
- Br J Dermatol. 2023 Mar 30;188(4):499-505
- J Am Acad Dermatol. 2023 Feb;88(2):388-394



<u>Example:</u> Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study.

	Controls						
	Controls N value	Cases N value	p-value SD	Controls Cases		p-value SD	analysis o
				N value	N value		the TriNe
CLE							
Age at Index (years) <sup>a</sup>	4,343,385 45.6527 (19.8966)	30,070 51.0767 (16.1117)	<0.0001 0.2996	30,070 51.5357 (15.9960)	30,070 51.0767 (16.1117)	0.0005 0.0286	platform
Female <sup>a</sup>	2,505,311 57.68%	23,203 77.16%	<0.0001 0.4250	23,163 77.03%	23,203 77.16%	0.6979 0.0032	
Male	1,836,002 42.27%	6859 22.81%	<0.0001 0.4246	6902 22.95%	6859 22.81%	0.6764 0.0034	a
Unknown Gender	2072 0.05%	10 0.03%	0.2523 0.0072	10 0.03%	10 0.03%	1.0000 0.0000	_
White	2,931,370 67.49%	20,166 67.06%	0.1153 0.0091	20,408 67.87%	20,166 67.06%	0.0352 0.0172	Intracra
B <b>l</b> ack or African American <sup>®</sup>	703,229 16.19%	5076 16.88%	0.0012 0.0186	5087 16.92%	5076 16.88%	0.9047 0.0010	
Asian	140,399 3.23%	498 1.66%	<0.0001 0.1022	794 2.64%	498 1.66%	<0.0001 0.0679	Sequelae of cerebro
Unknown Race	551,362 1.69%	4192 13.94%	<0.0001 0.0367		4192 13.94%	<0.0001 0.0526	Stenosis of pr
Not Hispanic or Latino <sup>®</sup>	3,119,470 71.82%	21,960 73.03%		21,940 72.96%	21,960 73.03%	0.8543 0.0015	
Hispanic or Latino	348,510 8.02%	1961 6.52%	<0.0001 0.0579		1961 6.52%	<0.0001 0.0375	Cerebro
Unknown Ethnicity	875,405 20.16%	6149 20.45%	0.2053 0.0073		6149 20.45%	0.0063 0.0223	
Nicotine dependence	409,432 9.43%	8364 27.82%	<0.0001 0.4861		8364 27.82%	0.7499 0.0026	
Overweight and obesity <sup>a</sup>	828,700 19.08%	7740 25.74%	<0.0001 0.1602		7740 25.74%	0.3918 0.0070	
Disorders of lipoprotein metabolism <sup>a</sup>	1,552,263 35.74%	10,033 33.37%	<0.0001 0.0499		10,033 33.37%	0.9862 0.0001	
Essential hypertension <sup>a</sup>	1,434,758 33.03%	13,799 45.89%		13,815 45.94%	13,799 45.89%	0.8958 0.0011	
Diabetes mellitus <sup>a</sup>	566,102 13.03%	8577 28.52%	<0.0001 0.3889		8577 28.52%	0.4380 0.0063	b
Chronic lower respiratory diseases <sup>1</sup>	763,086 17.57%	8701 28.94%	<0.0001 0.2715		8701 28.94%	0.6789 0.0034	
Chronic kidney disease <sup>®</sup>	198,225 4.56%	4324 14.38%	<0.0001 0.3400		4324 14.38%	0.7096 0.0030	Peripheral v
Neoplasms <sup>3</sup>	1,084,571 24.97%	14,636 48.67%	<0.0001 0.5070	14,534 48.33%	14,636 48.67%	0.4053 0.0068	
DLE							
Age at Index (years)*	4,343,385 45.6527 (19.8966)	27,187 50.6637 (16.0783)		27,187 51.1223 (16.0271)	27,187 50.6637 (16.0783)	0.0009 0.0286	Chronic ischer
Female <sup>a</sup>	2,505,311 57.68%	20,992 77.21%		20,935 77.00%	20,992 77.21%	0.5607 0.0050	Other disorders of c
Male	1,836,002 42.27%	6189 22.77%	<0.0001 0.4257		6189 22.77%	0.5334 0.0053	isea
Unknown Gender	2072 0.05%	10 0.04%	0.4106 0.0053		10 0.04%	1.0000 0.0000	Other disorders of arter
White	2,931,370 67.49%	18,233 67.07%		18,540 68.19%	18,233 67.07%	0.0049 0.0241	Other disorders of after
Black or African American <sup>a</sup>	703,229 16.19%	4788 17.61%	<0.0001 0.0379		4788 17.61%	0.0936 0.0144	
Asian	140,399 3.23%	459 1.69%	<0.0001 0.0998		459 1.69%	<0.0001 0.0637	Pulmon
Unknown Race	551,362 12.69%	3578 13.16%	0.0213 0.0139		3578 13.16%	<0.0001 0.0435	Aortic aneurys
Not Hispanic or Latino®	3,119,470 71.82%	20,201 74.30%	<0.0001 0.0560		20,201 74.30%	0.5305 0.0054	,
Hispanic or Latino	348,510 8.02%	1851 6.81%	<0.0001 0.0464		1851 6.81%	0.0006 0.0295	
Unknown Ethnicity	875,405 20.16%	5135 18.89%	<0.0001 0.0320		5135 18.89%	0.1152 0.0135	Hypertens
Nicotine dependence	409,432 9.43%	7947 29.23%	<0.0001 0.5181		7947 29.23%	0.5971 0.0045	Second
Overweight and obesity	828,700 19.08%	7223 26.57%	<0.0001 0.1791		7223 26.57%	0.4212 0.0069	Hypertensive chron
Disorders of lipoprotein metabolism	1,552,263 35.74%	9122 33.55%	<0.0001 0.0459		9122 33.55%	0.3596 0.0079	••
Essential hypertension	1,434,758 33.03%	12,706 46.74%		12,741 46.86%	12,706 46.74%	0.7636 0.0026	Hypertensive heart & chron
Diabetes mellitus	566,102 13.03%	8070 29.68%	<0.0001 0.4149		8070 29.68%	0.0601 0.0161	
Chronic lower respiratory diseases	763,086 17.57%	8094 29.77%	<0.0001 0.2901		8094 29.77%	0.6865 0.0035	
Chronic kidney disease	198,225 4.56%	4087 15.03%	<0.0001 0.3577		4087 15.03%	0.3793 0.0075	
Neoplasms <sup>a</sup>	1,084,571 24.97%	13,586 49.97%	<0.0001 0.5347	13,626 50.12%	13,586 49.97%	0.7315 0.0029	
SCLE Age at Index (years) <sup>a</sup>	4,343,385 45.6527 (19.8966)	1609 58.1541 (15.1819)	<0.0001 0.7064	1609 58.4891 (14.8447)	1609 58.1541 (15.1819)	0.5269 0.0223	С
Fema <b>l</b> e <sup>®</sup>	2,505,311 57.68%	1244 77.32%	<0.0001 0.4287		1244 77.32%	0.7373 0.0118	
-emaie Male	1,836,002 42.27%	365 22.69%	<0.0001 0.428/		365 22.69%	0.7690 0.0104	Venous embolisi
unknown Gender	2072 0.05%	0 0.00%	0.3809 0.0309		0 0.00%	0.0015 0.1118	•
White	2,931,370 67.49%	1176 73.09%	<0.0001 0.1227		1176	0.0015 0.1118	Other
WRITE Black or African American	703,229 16.19%	11/6 /3.09%	<0.0001 0.122/		11/1	10590	Disorders of lymphatic vesse
Asian	140,399 3.23%	13 0.81%	<0.0001 0.2845				District of
Unknown Race	551,362 12.69%	300 18.65%	<0.0001 0.1/30			1	Phlebitis and
Not Hispanic or Latino	3,119,470 71.82%	1110 68.99%	0.0115 0.0621		Hio	hly	Varicose veins of
Hispanic or Latino	348,510 8.02%	44 2.74%	<0.0001 0.2361	426 7 920	<u> </u>	1	
rnspanic of Latino	340,310 0.02%	44 2./4%	<0.0001 0.2301	120 7.05%	granular da	ita allowing	
						ropensity	
					טו טכנוסכ ט	TOTAL INTE	i e e e e e e e e e e e e e e e e e e e



**CLE**: Cutaneous

# **Actinic keratosis on TriNetX**

#### Number of electronic health records with ICD10CM:L57.0 (actinic keratosis)

Global Collaborative Network	1,108,477
US Collaborative Network	1,074,538
EMEA Collaborative Network (Europe)	30,030
LATAM Collaborative Network (Latin America)	2,981
APAC Collaborative Network (Asia-Pacific)	928





# WHY US?

Great network of dermatologists and plastic surgeons collecting samples from healthy and diseased skin

Our vision is
to provide our clients and
partners with the highest
quality research in investigative
dermatology and trichology –
from basic science to
translational applied and contract
research of high relevance for
clinical applications.

World-class scientific leadership & international team Clinicallyrelevant ex vivo and in vivo models

Strong
academic
background &
publication
record

#### What we can do for our clients:

- Conceptualize & build proof-of-concept studies
- Carry out full service portfolio for pre-clinical skin & hair research (in vitro/ex vivo assays, and humanized mouse models)
- Investigate side effects in the skin or hair follicle
- Establish novel cutting edge methodologies and techniques
- Design tailor-made & customized assays for all needs
- Identify, characterize, or validate novel targets and therapeutics for skin & hair disorders
- Discover mechanistic action stories, biomarkers & predictors of response
- Conduct investigator initiated skin & hair clinical trials
- Provide access to human healthy & diseased skin and hair specimen
- Prepare comprehensive project reports & manuscript drafts

sponse Global client

list &

testimonials

Our ambition is to

establish and refine research techniques:

Advanced Methodology

**Program** 

Investigative
dermatology:
Acne Vulgaris, Atopic
Dermatitis, Psoriasis,
Alopecia Areata,
Androgenic Alopecia,
Hidradenitis Suppurativa,
Vitiligo, Chronic Itch,
Prurigo Nodularis,
etc.

Biobank:
Full access to skin
& hair samples
(patients & healthy subjects)

Exceptional state-of-the-art research technology We are supported by world-wide recognized experts in dermatology